Article
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient.
American journal of hematology - 1 Dec 2006
Law Joanna K, Ali Jaber Al, Harrigan P Richard, Sherlock Christopher H, Savage Kerry J, Yoshida Eric M
Abstract excerpt
Hepatitis B reactivation is a well-known complication during or after chemotherapy in chronic hepatitis B (HBV) carriers. The current practice guidelines in Canada and the United States recommends patients receive antiviral prophylaxis prior to the onset of chemotherapy in chronic HBV carriers with lamivudine. We report a case of a 57-year-old man with follicular lymphoma on lamivudine prophylaxis and no clinical...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Drug Resistance, Viral
- Fatal Outcome
- Hepatitis B, Chronic
- Humans
- Lamivudine
- Liver Cirrhosis
- Lymphoma, Follicular
- Male
- Middle Aged